Adrian Gadano
Adrian Gadano is an expert in Hepatology at Hospital Italiano de Buenos Aires (Argentina). As of October 2026, ScienceLeadR ranks Adrian Gadano in the top 1% of experts worldwide for Hepatitis, and in the top 1% of experts in Argentina for MASH and Alcohol-Induced Disorders. Adrian Gadano has authored 361 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 2 of them ongoing. SLR score: 1,226 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 361
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Portal vein thrombosis increases short-term mortality among hospitalized patients with cirrhosis in a global cohort. PMID 42766768 — liver transplantation, mortality, non-alcoholic fatty liver disease, portal vein, thrombosis, veins, hepatitis | Liver Transpl | 2026 | 0 |
| Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026. PMID 42613687 — liver diseases, hypertension, carcinoma, hepatocellular, cholangitis, fibrosis, non-alcoholic fatty liver disease, liver, hypertension, portal, therapeutics, hepatitis, peroxisome proliferator-activated receptors | Liver Int | 2026 | 0 |
| Corrigendum to "Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts" [J Hepatol 85 (2026) 91-105]. PMID 42502052 — liver diseases, acute-on-chronic liver failure, liver, liver failure | J Hepatol Top journal | 2026 | 0 |
| Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis. PMID 42457041 — liver diseases, carvedilol, liver transplantation, mortality, acute-on-chronic liver failure, propranolol, kidney, liver, sepsis, diagnosis, therapeutics, renal replacement therapy, hemodynamics, acute kidney injury | J Hepatol Top journal | 2026 | 0 |
| Steatotic liver disease in Latin America: current views and perspectives. PMID 42298140 — liver diseases, genes, liver | Nat Rev Gastroenterol Hepatol Top journal | 2026 | 1 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 4
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes) NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic | Phase 3 | Recruiting | 2025 |
| Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH) NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map